CASI Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics, particularly in the fields of hematology and oncology. The company focuses on addressing unmet medical needs by acquiring and advancing various pharmaceutical products. Among its offerings, EVOMELA is notable for its role as a conditioning treatment prior to autologous stem cell transplants in multiple myeloma patients, while its portfolio also includes CID-103, CNCT19, MARQIBO, ZEVALIN, and ENMD-2076. CASI Pharmaceuticals primarily generates revenue through the sales of EVOMELA, and it aims to establish itself as a leader in the biopharmaceutical sector by leveraging its expertise in drug development and regulatory processes, particularly in the China market.
Precision Autoimmune Therapeutics is a clinical-stage innovative drug development company focused on precision therapeutics for patients with autoimmune and inflammatory diseases.
Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provide effective treatment for malignant hematological neoplasms such as leukemia and lymphoma.
Miikana Therapeutics is a privately held biotechnology company dedicated to the discovery and development of innovative medicines for cancer treatment. The company engages in internal drug discovery programs, complemented by in-licensing pre-clinical and early clinical oncology drug candidates to enhance its portfolio. Through these efforts, Miikana Therapeutics aims to address unmet medical needs in oncology and contribute to advancements in cancer care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.